The potential role of anticoagulant therapy for the secondary prevention of ischemic events post-acute coronary syndrome

Anthony Camuglia, Kathryn Waddell-Smith, Christopher Hammett, Philip Aylward

    Research output: Contribution to journalArticle

    2 Citations (Scopus)

    Abstract

    The use of dual antiplatelet therapy has led to a substantial reduction in ischemic events post-acute coronary syndrome (ACS). Despite this, recurrent event rates remain high. Recent research has combined antiplatelet with anticoagulant therapy to reduce recurrent event rates further. Compared with standard medical therapy, rivaroxaban demonstrated improved efficacy outcomes and significantly reduced mortality after an ACS. Although clear benefits of novel oral anticoagulants post-ACS have been proven, concerns regarding bleeding are still a barrier to widespread use. This review explores key trials of dual antiplatelet therapy and examines the latest research in anticoagulation aiming to optimize clinical outcomes post-ACS.

    Original languageEnglish
    Pages (from-to)2151-2167
    Number of pages17
    JournalCurrent Medical Research and Opinion
    Volume30
    Issue number11
    DOIs
    Publication statusPublished - 2014

    Fingerprint Dive into the research topics of 'The potential role of anticoagulant therapy for the secondary prevention of ischemic events post-acute coronary syndrome'. Together they form a unique fingerprint.

  • Cite this